Investment Summary

KKR and DCP Capital Invest In Gambol Pet

On February 26, 2017, private equity firms KKR and DCP Capital invested in food company Gambol Pet

Investment Highlights
  • This is KKR’s 10th and DCP Capital’s 1st transaction in the Food sector.
  • This is KKR’s 16th and DCP Capital’s 1st transaction in China.

Investment Summary

Date 2017-02-26
Target Gambol Pet
Sector Food
Investor(s) KKR
DCP Capital
Deal Type Growth Capital

Target

Gambol Pet

Liaocheng City, China
Gambol provides a wide range of pet food products including dry food, wet food, real meat jerky treats, rawhide chew, dental bone, etc. Gambol Pet was founded in 2006 and is based in Liaocheng City, China.

Search 214,239 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Investor(S) 2

Investor

KKR

New York, New York, United States

Investor Investor Investor Investor Investor


Category Private Equity Firm
Founded 1976
PE ASSETS 267.0B USD
Size Mega
Type Sector Agnostic
DESCRIPTION
KKR's office in Menlo Park, California.
KKR's office in Menlo Park, California.

KKR is a global investment firm founded by Jerome Kohlberg, Henry Kravis, and George Roberts. The Firm is separated into several business segments including private markets, public markets, capital markets, and other principal activities. KKR's private equity practice invests in management buyouts, take privates, corporate divestitures, industry consolidations, and partnerships with family-owned companies. KKR will invest in a broad range of industries and companies and will consider businesses throughout North America, Europe, Asia, and Australia/New Zealand. Sectors of interest include chemicals, consumer products, energy and natural resources, financial services, healthcare, industrial, media/communications, retail, and technology. In addition to its traditional principal investment activity business, KKR also invests in infrastructure assets. KKR was formed in 1976 and is based in New York, New York.


DEAL STATS #
Overall 229 of 499
Sector: Food M&A 10 of 16
Type: Growth Capital M&A Deals 36 of 81
Country: China M&A 16 of 29
Year: 2017 M&A 9 of 41
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2017-02-21 Telxius

Madrid, Spain

Telxius is a provider of telecom infrastructure services in Europe and the Americas and operates through the sub-sea cable and telecom tower segments. Telxius is based in Madrid, Spain.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2017-02-27 Cherwell Software

Colorado Springs, Colorado, United States

Cherwell Software LLC is an IT and enterprise service management, Cherwell Software empowers IT to lead through the use of powerful and intuitive technology that enables better, faster, and more affordable innovation. The Cherwell® Service Management platform is built from the ground up with a unique codeless architecture that enables rapid time to value, infinite flexibility, and frictionless upgrades every time—at a fraction of the cost and complexity of legacy solutions. Cherwell Software was founded in 2004 and is based in Colorado Springs, Colorado.

Buy -
DESCRIPTION

DCP is a private equity firm focused on long-term partnerships with management teams in companies across Asia. The Firm seeks businesses with growth potential in a variety of industries including business services, consumer products, distribution, food, manufacturing, financial services, real estate, and staffing. DCP is headquartered in Beijing, China.


DEAL STATS #
Overall 2 of 15
Sector: Food M&A 1 of 4
Type: Growth Capital M&A Deals 1 of 5
Country: China M&A 1 of 13
Year: 2017 M&A 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2015-05-21 Ambrx

San Diego, California, United States

Ambrx is a clinical-stage biopharmaceutical company with a proprietary synthetic biology technology platform to design and develop next-generation antibody-drug conjugates (ADCs). The company is advancing a focused portfolio of clinical and preclinical programs designed to optimize efficacy and safety of its candidate therapeutics in multiple cancer indications, including ARX517, its proprietary ADC targeting PSMA for metastatic castration-resistant prostate cancer (mCRPC); ARX788, its proprietary ADC targeting human epidermal growth factor receptor 2 (HER2) for metastatic HER2+ breast cancer; and ARX305, its proprietary ADC targeting CD-70 for renal cell carcinoma. Ambrx was founded in 2003 and is based in San Diego, California.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2018-02-01 MFS Technology

Singapore, Singapore

MFS Technology is a printed circuit board solutions provider with a strategic focus on end industries such as medical, data storage, automotive and industrial control. MFS Technology was founded in 1989 and is based in Singapore.

Buy -